ArticleResearch square2024

FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10S59L by reducing the PINK1/Parkin pathway.

Swati Maitra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.